冒烟型多发性骨髓瘤的争议：寻找治疗起始的最佳方法
Controversies in smoldering multiple myeloma: finding the optimal approach for treatment initiation.
作者信息
Ludwig Heinz, Schreder Martin
机构信息
Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology with Outpatient Department, and Palliative Care, Clinic Ottakring, 1160 Vienna, Austria.
Department of Medicine I, Center for Oncology, Hematology with Outpatient Department, and Palliative Care, Clinic Ottakring, 1160 Vienna, Austria.
出版信息
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae266.
Abstract
This commentary focuses on data in favor of early treatment initiation or a cautious wait-and-see strategy in smoldering multiple myeloma.
摘要
本评论聚焦于支持在冒烟型多发性骨髓瘤中尽早开始治疗或采取谨慎观望策略的数据。
相似文献
1
Controversies in smoldering multiple myeloma: finding the optimal approach for treatment initiation.冒烟型多发性骨髓瘤的争议：寻找治疗起始的最佳方法
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae266.
2
Clinical Controversies in the Management of Smoldering Multiple Myeloma.冒烟型多发性骨髓瘤治疗中的临床争议
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-6. doi: 10.1200/EDBK_278911.
3
Shall we treat smoldering multiple myeloma in the near future?我们是否应该在不久的将来治疗冒烟型多发性骨髓瘤？
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204. doi: 10.1182/asheducation-2017.1.194.
4
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.高危冒烟型骨髓瘤与多发性骨髓瘤的早期检测：当前模型、治疗目标及临床意义。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101152. doi: 10.1016/j.beha.2020.101152. Epub 2020 Jan 25.
5
Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study.淀粉样轻链淀粉样变性对多发性骨髓瘤临床特征及预后的影响：一项单中心回顾性研究
Cancer Manag Res. 2021 Feb 11;13:1343-1356. doi: 10.2147/CMAR.S287922. eCollection 2021.
6
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.卡非佐米、来那度胺和地塞米松治疗后序贯来那度胺维持治疗高危冒烟型骨髓瘤患者预防症状性多发性骨髓瘤的Ⅱ期非随机对照试验
JAMA Oncol. 2021 Nov 1;7(11):1678-1685. doi: 10.1001/jamaoncol.2021.3971.
7
The consultant's guide to smoldering multiple myeloma.冒烟型多发性骨髓瘤的顾问指南。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):551-559. doi: 10.1182/hematology.2022000355.
8
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma.多发性骨髓瘤当前挑战与新兴方法的专家观点：白血病、淋巴瘤和多发性骨髓瘤首次弥合差距会议的叙述性综述
Clin Lymphoma Myeloma Leuk. 2025 Sep;25(9):635-645. doi: 10.1016/j.clml.2025.03.008. Epub 2025 Mar 11.
9
Smoldering Myeloma Treatment: Who, What, and When.冒烟型骨髓瘤的治疗：对象、方法及时机
Cancer J. 2021;27(3):185-189. doi: 10.1097/PPO.0000000000000528.
10
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.来那度胺早期干预高危冒烟型多发性骨髓瘤的获益：新出现的数据及其有前景的临床影响。
Expert Rev Hematol. 2021 Dec;14(12):1059-1069. doi: 10.1080/17474086.2021.1984225. Epub 2021 Sep 28.
本文引用的文献
1
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.评估冒烟型骨髓瘤临床试验中的早期干预：一项系统综述
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae219.
2
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.高危冒烟型骨髓瘤的治疗策略：卡非佐米、来那度胺和地塞米松（KRd）治疗后进行移植、KRd 巩固治疗和 Rd 维持治疗。
J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22.
3
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.临床医生对冒烟型骨髓瘤治疗的偏好：一项横断面调查。
EClinicalMedicine. 2023 Oct 24;65:102272. doi: 10.1016/j.eclinm.2023.102272. eCollection 2023 Nov.
4
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.CLL12 试验：伊布替尼对比安慰剂用于初治、早期慢性淋巴细胞白血病。
Blood. 2022 Jan 13;139(2):177-187. doi: 10.1182/blood.2021010845.
5
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.全基因组测序揭示进展性与稳定性骨髓瘤前体疾病是两种截然不同的实体。
Nat Commun. 2021 Mar 25;12(1):1861. doi: 10.1038/s41467-021-22140-0.
6
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).国际骨髓瘤工作组冒烟型多发性骨髓瘤（SMM）的风险分层模型。
Blood Cancer J. 2020 Oct 16;10(10):102. doi: 10.1038/s41408-020-00366-3.
7
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.早期采用 FCR 治疗与观察等待对 Binet A 期高危慢性淋巴细胞白血病（CLL）患者的影响：一项随机 3 期试验。
Leukemia. 2020 Aug;34(8):2038-2050. doi: 10.1038/s41375-020-0747-7. Epub 2020 Feb 18.
8
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.随机 Lenalidomide 对照观察冒烟型多发性骨髓瘤。
J Clin Oncol. 2020 Apr 10;38(11):1126-1137. doi: 10.1200/JCO.19.01740. Epub 2019 Oct 25.
9
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.冒烟型多发性骨髓瘤的风险分层：游离轻链和基于群组的轨迹建模的预测价值。
Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998.
10
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.纳入修订后 IMWG 诊断标准的冒烟型多发性骨髓瘤的风险分层。
Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.
Zotero 插件